---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001759"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:41:20.349852+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve reincorporation to Nevada and name change to Channel Therapeutics; board adds $500k to buyback

## Summary
- Proposal 4 approved: reincorporation from Delaware to Nevada and renaming to Channel Therapeutics Corp. (2.6M for, 2.3K against, 929.7K abstain).
- Board authorizes amendment to repurchase plan: adds $500k (total $750k) and extends termination to June 30, 2025.
- Proposal 1: all five director nominees elected (Todd Davis, Ezra Friedberg, Francis Knuettel II, Dr. Richard Malamut, Chia-Lin Simmons).
- Proposal 2: amendment to 2023 Equity Incentive Plan increasing authorized shares approved (3.5M for).
- Proposal 5: Marcum LLP ratified as independent auditor for FY2024 (3.9M for).

## SEC filing metadata
- accession: 0001753926-24-001759
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001759/0001753926-24-001759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001759/g084503_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001759
- JSON: https://secwatch.observer/filing/0001753926-24-001759.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001759.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.